Business Context and Reporting Period
Company: Penumbra, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2020
Context: The filing serves as a Regulation FD disclosure to correct an inaccurate analyst estimate regarding product revenue mix and to announce an upcoming CEO discussion with Bank of America scheduled for December 8, 2020.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue totals, profit figures, cash flow, margins, debt, or liquidity metrics. The only specific financial data point disclosed is:
- JET 7 Xtra Flex Revenue Contribution: 7.5% of total revenue for the fiscal quarter ended September 30, 2020.
Material Changes and Corrections
The primary material update in this filing is a correction of public information:
- Analyst Estimate Correction: An analyst note published on December 6, 2020, contained an inaccurate estimate of the revenue percentage attributable to the Penumbra JET 7 Reperfusion Catheter with Xtra Flex technology for the quarter ended September 30, 2020. The Company clarifies the correct figure is 7.5%.
Guidance, Outlook, and Management Commentary
Upcoming Event: The Company is scheduled to participate in a CEO Discussion with Bank of America on Tuesday, December 8, 2020, at 8:30 a.m. Eastern Time.
Expected Topics: Updates and information regarding the Company's vascular and neuro businesses across a range of topics.
Legal Disclaimer: The information furnished in this 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly set forth by specific reference.
Investor Verification Checklist
- Verify the corrected 7.5% revenue contribution of the JET 7 Xtra Flex product for the quarter ended September 30, 2020, against prior analyst estimates.
- Monitor the transcript or summary of the CEO Discussion with Bank of America on December 8, 2020, for further updates on vascular and neuro business performance.
- Note that this filing does not contain full quarterly financial results; refer to the Company's Form 10-Q for the quarter ended September 30, 2020, for complete financial data.